Last reviewed · How we verify
IGF-Methotrexate conjugate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
IGF-Methotrexate conjugate (IGF-Methotrexate conjugate) — IGF Oncology, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IGF-Methotrexate conjugate TARGET | IGF-Methotrexate conjugate | IGF Oncology, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IGF-Methotrexate conjugate CI watch — RSS
- IGF-Methotrexate conjugate CI watch — Atom
- IGF-Methotrexate conjugate CI watch — JSON
- IGF-Methotrexate conjugate alone — RSS
Cite this brief
Drug Landscape (2026). IGF-Methotrexate conjugate — Competitive Intelligence Brief. https://druglandscape.com/ci/igf-methotrexate-conjugate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing